BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone919-582-9050
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$55.64 million
Profitability
Miscellaneous
Employees164
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."
How were BioDelivery Sciences International's earnings last quarter?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its earnings results on Monday, May, 6th. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.03. The specialty pharmaceutical company earned $19.77 million during the quarter, compared to analysts' expectations of $19.60 million. BioDelivery Sciences International had a negative net margin of 42.09% and a negative return on equity of 43.40%. View BioDelivery Sciences International's Earnings History.
When is BioDelivery Sciences International's next earnings date?
What price target have analysts set for BDSI?
4 brokers have issued 12-month price targets for BioDelivery Sciences International's stock. Their predictions range from $5.00 to $8.00. On average, they expect BioDelivery Sciences International's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.
What is the consensus analysts' recommendation for BioDelivery Sciences International?
What are Wall Street analysts saying about BioDelivery Sciences International stock?
Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
- 1. According to Zacks Investment Research, "BioDelivery reported encouraging first-quarter results wherein earnings and sales surpassed the respective estimates. The company secured improved positioning in several managed care contracts, providing preferred access to Belbuca. The company’s efforts have brought 115 million patients under preferred coverage so far in 2019, having started 2018 with 7 million. The company’s efforts boosted the drug’s sales and the momentum is expected to continue in 2019. Belbuca’s prescriptions grew sequentially in the past few quarters. The acquisition of U.S. rights of Symproic strengthened the chronic pain portfolio. BioDelivery’s shares have outperformed the industry so far this year. However, given the lackluster performance of Bunavail, BioDelivery has decided to reduce spending on the drug. The company’s portfolio and its pipeline may face severe competition as these target a highly genericized and crowded market." (5/21/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post BDSI’s recent acquisition of U.S. commercial rights to Symproic, and equity raise, we are updating our model and reiterating our Overweight rating and 12-month price target of $8. BDSI has built a strong commercial team around Belbuca, and the acquisition leverages the company’s commercial strengths, and footprint, to grow its portfolio. We view the acquisition of Symproic as a positive as it diversifies the company’s revenue away from a single product, Belbuca, and can add a meaningful revenue contribution of $75MM + without the need for any significant increase in spending." (4/16/2019)
- 3. HC Wainwright analysts commented, "Our $6 12-month target (from $5) is based on a DCF reflecting strong Belbuca growth to nearly $180M by 2022, company cash-flow breakeven by end-2019, and overall profitability in 2020. Our DCF reflects a 10% WACC discount and negative -15% terminal value beyond 2026, and includes 90M fully diluted shares vs. currently reported 70M) to account for, among other shares, the substantial dilution from convertible preferred series B shares that were issued in the 2018 $50M financing ($1.80/share conversion price)." (3/15/2019)
Has BioDelivery Sciences International been receiving favorable news coverage?
News articles about BDSI stock have been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioDelivery Sciences International earned a news impact score of 1.6 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for BioDelivery Sciences International.
Who are some of BioDelivery Sciences International's key competitors?
Some companies that are related to BioDelivery Sciences International include Ironwood Pharmaceuticals (IRWD), Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL), Nabriva Therapeutics (NBRV), Innoviva (INVA), Apellis Pharmaceuticals (APLS), Heron Therapeutics (HRTX), Cambrex (CBM), Gossamer Bio (GOSS), Esperion Therapeutics (ESPR), Turning Point Therapeutics (TPTX), Aimmune Therapeutics (AIMT), Opko Health (OPK), Corcept Therapeutics (CORT) and Eidos Therapeutics (EIDX).
What other stocks do shareholders of BioDelivery Sciences International own?
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the folowing people:
- Mr. Herm Cukier, CEO & Director (Age 52)
- Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 54)
- Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50)
- Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 58)
- Mr. Ernest Robert De Paolantonio CPA, MBA, Exec. Officer (Age 66)
Who are BioDelivery Sciences International's major shareholders?
BioDelivery Sciences International's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (2.62%), Emerald Advisers LLC (2.44%), Emerald Mutual Fund Advisers Trust (2.19%), 1492 Capital Management LLC (0.91%), Laurion Capital Management LP (0.81%) and Cadence Capital Management LLC (0.75%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, Mark A Sirgo and Paolantonio Ernest Robert De. View Institutional Ownership Trends for BioDelivery Sciences International.
Which institutional investors are selling BioDelivery Sciences International stock?
BDSI stock was sold by a variety of institutional investors in the last quarter, including Knott David M, 1492 Capital Management LLC, Alpha Omega Wealth Management LLC, Alpine Global Management LLC and Bank of Montreal Can. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, Mark A Sirgo and Paolantonio Ernest Robert De. View Insider Buying and Selling for BioDelivery Sciences International.
Which institutional investors are buying BioDelivery Sciences International stock?
BDSI stock was purchased by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, ClariVest Asset Management LLC, Laurion Capital Management LP, Rubric Capital Management LP, Cadence Capital Management LLC, Nordea Investment Management AB and Advisory Services Network LLC. View Insider Buying and Selling for BioDelivery Sciences International.
How do I buy shares of BioDelivery Sciences International?
Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioDelivery Sciences International's stock price today?
One share of BDSI stock can currently be purchased for approximately $4.52.
How big of a company is BioDelivery Sciences International?
BioDelivery Sciences International has a market capitalization of $404.22 million and generates $55.64 million in revenue each year. The specialty pharmaceutical company earns $-33,870,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. BioDelivery Sciences International employs 164 workers across the globe.View Additional Information About BioDelivery Sciences International.
What is BioDelivery Sciences International's official website?
How can I contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]
MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
